Lee Hambright
Stock Analyst at Bernstein
(3.32)
# 1,002
Out of 4,711 analysts
22
Total ratings
68.75%
Success rate
10.81%
Average return
Main Sectors:
Stocks Rated by Lee Hambright
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDT Medtronic | Maintains: Outperform | $96 → $97 | $81.03 | +19.71% | 2 | Nov 20, 2024 | |
| PODD Insulet | Initiates: Outperform | $300 | $266.57 | +12.54% | 1 | Nov 6, 2024 | |
| TNDM Tandem Diabetes Care | Initiates: Outperform | $42 | $35.91 | +16.96% | 1 | Nov 6, 2024 | |
| DXCM DexCom | Maintains: Outperform | $82 → $86 | $80.04 | +7.45% | 2 | Oct 25, 2024 | |
| BSX Boston Scientific | Maintains: Outperform | $92 → $100 | $88.95 | +12.42% | 1 | Oct 24, 2024 | |
| ABT Abbott Laboratories | Maintains: Outperform | $133 → $138 | $114.23 | +20.81% | 2 | Oct 17, 2024 | |
| ISRG Intuitive Surgical | Maintains: Outperform | $350 → $365 | $524.43 | -30.40% | 2 | May 31, 2023 | |
| ZBH Zimmer Biomet Holdings | Maintains: Market Perform | $136 → $152 | $107.12 | +41.90% | 1 | May 3, 2023 | |
| JNJ Johnson & Johnson | Downgrades: Market Perform | $183 | $144.47 | +26.67% | 4 | Mar 16, 2022 | |
| SYK Stryker | Upgrades: Outperform | $288 → $295 | $364.60 | -19.09% | 3 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $132 → $135 | $74.81 | +80.46% | 3 | Mar 16, 2022 |
Medtronic
Nov 20, 2024
Maintains: Outperform
Price Target: $96 → $97
Current: $81.03
Upside: +19.71%
Insulet
Nov 6, 2024
Initiates: Outperform
Price Target: $300
Current: $266.57
Upside: +12.54%
Tandem Diabetes Care
Nov 6, 2024
Initiates: Outperform
Price Target: $42
Current: $35.91
Upside: +16.96%
DexCom
Oct 25, 2024
Maintains: Outperform
Price Target: $82 → $86
Current: $80.04
Upside: +7.45%
Boston Scientific
Oct 24, 2024
Maintains: Outperform
Price Target: $92 → $100
Current: $88.95
Upside: +12.42%
Abbott Laboratories
Oct 17, 2024
Maintains: Outperform
Price Target: $133 → $138
Current: $114.23
Upside: +20.81%
Intuitive Surgical
May 31, 2023
Maintains: Outperform
Price Target: $350 → $365
Current: $524.43
Upside: -30.40%
Zimmer Biomet Holdings
May 3, 2023
Maintains: Market Perform
Price Target: $136 → $152
Current: $107.12
Upside: +41.90%
Johnson & Johnson
Mar 16, 2022
Downgrades: Market Perform
Price Target: $183
Current: $144.47
Upside: +26.67%
Stryker
Mar 16, 2022
Upgrades: Outperform
Price Target: $288 → $295
Current: $364.60
Upside: -19.09%
Mar 16, 2022
Upgrades: Outperform
Price Target: $132 → $135
Current: $74.81
Upside: +80.46%